Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.96 +0.26 (+0.77%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
35 36 Next >
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered... 
Via Benzinga
GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug
GlaxoSmithKline plc (NYSE: GSK) announced positive results from the ASCEND program comprised of five Phase 3 studies assessing daprodustat for anemia due to... 
Via Benzinga
Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell • McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion. • General... 
Via Benzinga
Daily Report: GlaxoSmithKline (GSK)
TalkMarkets Episode VII-6 Monday, 10/11/21 Stockpicker Star GlaxoSithKline (GSK) Healthcare Sector 
Via Talk Markets
Why Vir Biotechnology Stock Is Sliding Today
Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
Upgrades For IGM Biosciences Inc (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
Thursday Market Overview
If you are an IBM shareholder you now own something new Kyndryl. 
Via Talk Markets
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on. 
Via The Motley Fool
GlaxoSmithKline PLC Sets New Annual-High Share Price
GlaxoSmithKline PLC (NYSE: GSK) traded today at a new 12-month high of $42.71. Approximately 1.8 million shares have changed hands today, as compared to an average 30-day volume... 
Via Benzinga
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
GlaxoSmithKline plc (GSK) Q2 2021 Earnings Call Transcript
GSK earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GlaxoSmithKline Drops Research On Otilimab In COVID-19
GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years... 
Via Benzinga
Exposures COVID-19
Glaxo Reports Double-Digit Growth In Q3 Pharma, Vaccine Sales, Updates FY21 Guidance
GlaxoSmithKline Plc's (NYSE: GSK) turnover was £9.07 billion in Q3, up 5% Y/Y (actual exchange rate AER), 10% (constant exchange rate CER). Pharmaceuticals... 
Via Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M... 
Via Benzinga
GlaxoSmithKline: My Top Value Stock For The Week
GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very... 
Via Talk Markets
Chinese Growth Level
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?
J&J has set a high bar for its rivals. 
Via The Motley Fool
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
Why CureVac Stock Is Tumbling Today
The company is throwing in the towel on its first-generation COVID-19 vaccine candidate. 
Via The Motley Fool
Exposures COVID-19
Winners and Losers of Rising Energy Prices
Bond traders are back to work on Tuesday after taking Monday off for Columbus Day. Bonds are trading higher this morning as yields are falling slightly. Lower yields could pull... 
Via Benzinga
Why Did Ocugen Stock Skyrocket On Monday?
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What... 
Via Benzinga
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB... 
Via Talk Markets
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.